Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 159

1.

Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer.

Kirane A, Toombs JE, Ostapoff K, Carbon JG, Zaknoen S, Braunfeld J, Schwarz RE, Burrows FJ, Brekken RA.

Clin Cancer Res. 2012 Sep 15;18(18):5031-42. doi: 10.1158/1078-0432.CCR-12-0453. Epub 2012 Jul 24.

2.

Concurrent inhibition of NF-kappaB, cyclooxygenase-2, and epidermal growth factor receptor leads to greater anti-tumor activity in pancreatic cancer.

Ali S, Banerjee S, Schaffert JM, El-Rayes BF, Philip PA, Sarkar FH.

J Cell Biochem. 2010 May;110(1):171-81. doi: 10.1002/jcb.22523. Erratum in: J Cell Biochem. 2016 Aug;117(8):1961.

3.

Epithelial-mesenchymal transition increases tumor sensitivity to COX-2 inhibition by apricoxib.

Kirane A, Toombs JE, Larsen JE, Ostapoff KT, Meshaw KR, Zaknoen S, Brekken RA, Burrows FJ.

Carcinogenesis. 2012 Sep;33(9):1639-46. doi: 10.1093/carcin/bgs195. Epub 2012 Jun 7.

4.

Apricoxib upregulates 15-PGDH and PGT in tobacco-related epithelial malignancies.

St John MA, Wang G, Luo J, Dohadwala M, Hu D, Lin Y, Dennis M, Lee JM, Elashoff D, Lawhon T, Zaknoen SL, Burrows FJ, Dubinett SM.

Br J Cancer. 2012 Aug 7;107(4):707-12. doi: 10.1038/bjc.2012.203. Epub 2012 Jul 24.

5.

Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.

Wong MH, Xue A, Julovi SM, Pavlakis N, Samra JS, Hugh TJ, Gill AJ, Peters L, Baxter RC, Smith RC.

Clin Cancer Res. 2014 Aug 1;20(15):4047-58. doi: 10.1158/1078-0432.CCR-13-3377. Epub 2014 Jun 3.

7.

Anti-tumor activity of erlotinib in the BxPC-3 pancreatic cancer cell line.

Lu YY, Jing DD, Xu M, Wu K, Wang XP.

World J Gastroenterol. 2008 Sep 21;14(35):5403-11.

8.
9.

Apricoxib, a COX-2 inhibitor for the potential treatment of pain and cancer.

Rao PN, Grover RK.

IDrugs. 2009 Nov;12(11):711-22.

PMID:
19844858
10.

Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.

Bianco C, Giovannetti E, Ciardiello F, Mey V, Nannizzi S, Tortora G, Troiani T, Pasqualetti F, Eckhardt G, de Liguoro M, Ricciardi S, Del Tacca M, Raben D, Cionini L, Danesi R.

Clin Cancer Res. 2006 Dec 1;12(23):7099-107.

11.

The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer.

Dineen SP, Sullivan LA, Beck AW, Miller AF, Carbon JG, Mamluk R, Wong H, Brekken RA.

BMC Cancer. 2008 Nov 27;8:352. doi: 10.1186/1471-2407-8-352.

12.

Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts.

Iwai T, Moriya Y, Shirane M, Fujimoto-Ouchi K, Mori K.

Oncol Rep. 2012 Apr;27(4):923-8. doi: 10.3892/or.2011.1614. Epub 2011 Dec 30.

13.

Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts.

Wang X, Zhang L, O'Neill A, Bahamon B, Alsop DC, Mier JW, Goldberg SN, Signoretti S, Atkins MB, Wood CG, Bhatt RS.

Br J Cancer. 2013 Feb 5;108(2):319-26. doi: 10.1038/bjc.2012.591. Epub 2013 Jan 15.

14.

Apoptosis-inducing effect of erlotinib is potentiated by 3,3'-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer.

Ali S, Banerjee S, Ahmad A, El-Rayes BF, Philip PA, Sarkar FH.

Mol Cancer Ther. 2008 Jun;7(6):1708-19. doi: 10.1158/1535-7163.MCT-08-0354.

15.

Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.

Tortora G, Caputo R, Damiano V, Melisi D, Bianco R, Fontanini G, Veneziani BM, De Placido S, Bianco AR, Ciardiello F.

Clin Cancer Res. 2003 Apr;9(4):1566-72.

16.
17.

Inhibition of COX-2 in colon cancer modulates tumor growth and MDR-1 expression to enhance tumor regression in therapy-refractory cancers in vivo.

Rahman M, Selvarajan K, Hasan MR, Chan AP, Jin C, Kim J, Chan SK, Le ND, Kim YB, Tai IT.

Neoplasia. 2012 Jul;14(7):624-33.

18.

Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model.

Brandes F, Schmidt K, Wagner C, Redekopf J, Schlitt HJ, Geissler EK, Lang SA.

BMC Cancer. 2015 Feb 19;15:71. doi: 10.1186/s12885-015-1064-9.

19.

Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells.

Diep CH, Munoz RM, Choudhary A, Von Hoff DD, Han H.

Clin Cancer Res. 2011 May 1;17(9):2744-56. doi: 10.1158/1078-0432.CCR-10-2214. Epub 2011 Mar 8.

20.

Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.

Venkatasubbarao K, Peterson L, Zhao S, Hill P, Cao L, Zhou Q, Nawrocki ST, Freeman JW.

Mol Cancer. 2013 Sep 11;12(1):104. doi: 10.1186/1476-4598-12-104.

Supplemental Content

Support Center